查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲微生物組治療市場預測至 2030 年 - 區域分析 - 按類型、應用程式和最終用戶
市場調查報告書
商品編碼
1494523

歐洲微生物組治療市場預測至 2030 年 - 區域分析 - 按類型、應用程式和最終用戶

Europe Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type, Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 71 Pages | 訂單完成後即時交付

價格

2022年歐洲微生物組治療市場價值為9,774萬美元，預計到2030年將達到2.1252億美元；預計2022年至2030年複合年成長率為10.2%。

改善微生物組發現管道的資金流入推動歐洲微生物組治療市場

研究表明，微生物群的不平衡或破壞可能導致多種疾病，例如發炎性腸道疾病和肥胖，以及精神健康障礙。微生物組在整體健康中的作用的認知引起了人們對開發針對和調節微生物組的療法的濃厚興趣。此外，技術和研究工具的進步使得研究和操縱微生物組變得更加容易。新一代定序和宏基因組分析使人們能夠更深入地了解微生物群落及其功能。知識的增加為開發標靶療法開啟了新的可能性。例如，2023 年 3 月，德國微生物組生物技術公司 mbiomics GmbH 開發了第一代有效的基於微生物組的療法。它從 MIG Capital 獲得了 1300 萬美元（1500 萬美元）的融資。這筆資金將用於建立該平台，這將加速第一批候選藥物的識別，並加快臨床驗證的研究工作。隨著強力的臨床證據的出現，投資人開始注意到微生物組調節劑公司。增加的資金為公司提供了必要的資源，以克服與高開發和生產成本相關的挑戰，最終推動該領域向前發展。

歐洲微生物組治療市場概述

德國的微生物組治療研究公司致力於呼籲其他公司投資其研究活動，以提高微生物組產品開發研究的品質。 2023 年 3 月，專注於微生物組的德國生技公司 mbiomics GmbH 在 MIG Capital 領投的 A 輪融資中獲得約 1,500 萬美元（1,300 萬美元）。 mbiomics 利用所得收益建立了策略合作夥伴關係，顯著擴大了其在德國的慕尼黑實驗室設施和研發團隊。在一些 FMT 程序中，傳染源可能會從捐贈者轉移到患者身上，從而影響結果。因此，德國對微生物組或 FMT 程序的使用制定了特殊規定。在德國，FMT 藥物作為藥品進行監管；然而，只有當其他治療方法對艱難梭菌感染和腸道感染等病症無效時，才能使用該產品。因此，儘管微生物組治療研究的投資激增，但有關這些治療產品使用的法規可能會阻礙德國歐洲微生物組治療市場的成長。

歐洲微生物組治療市場收入及 2030 年預測（百萬美元）

歐洲微生物組治療市場細分

歐洲微生物組治療市場根據類型、應用、最終用戶和國家進行細分。

根據類型，歐洲微生物組治療市場分為治療方法和手術方法。到 2022 年，手術細分市場將佔據更大佔有率。

根據應用，歐洲微生物組治療市場分為代謝紊亂和肥胖、艱難梭菌感染、發炎性腸道疾病等。 2022 年，代謝紊亂和肥胖細分市場佔最大佔有率。

從最終用戶來看，歐洲微生物組治療市場包括醫院和診所、門診手術中心、家庭護理等。 2022 年，醫院和診所領域佔最大佔有率。

根據國家/地區，歐洲微生物組治療市場分為英國、德國、法國、義大利、西班牙和歐洲其他地區。 2022 年，德國在歐洲微生物組治療市場佔據主導地位。

Caelus Health BV、Enterome SA、Ferring Holdings SA、Vedanta Biosciences Inc 和 YSOPIA Bioscience SA 是歐洲微生物組治療市場上的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：歐洲微生物組治療市場格局

  • 概述
  • 歐洲PEST分析

第 5 章：歐洲微生物組治療市場 - 主要產業動態

  • 歐洲微生物組治療市場 - 主要產業動態
  • 主要市場促進因素
    • 腸道微生物群在維持人類健康的潛力
    • 資金流入改善微生物組發現管道
  • 主要市場限制
    • 開發和生產成本高
  • 主要市場機會
    • 加強研發以更了解人類微生物組
  • 未來主要趨勢
    • 人類微生物組治療的技術進步
  • 促進因素和限制的影響：

第 6 章：微生物組治療市場 - 歐洲市場分析

第 7 章：歐洲微生物組治療市場分析 - 類型

  • 療法
    • 概述
    • 治療市場、收入與 2030 年預測
  • 程式
    • 概述
    • 程序市場、收入和 2030 年預測

第 8 章：歐洲微生物組治療市場分析 - 應用

  • 代謝紊亂與肥胖
    • 概述
    • 代謝紊亂和肥胖市場、收入和 2030 年預測
  • C. 艱難梭菌感染 (CDI)
    • 概述
    • C. 艱難梭菌感染 (CDI) 市場、收入和 2030 年預測
  • 發炎性腸道疾病
    • 概述
    • 發炎性腸道疾病市場、收入和 2030 年預測
  • 其他
    • 概述
    • 其他市場、收入和 2030 年預測

第 9 章：歐洲微生物組治療市場分析 - 最終用戶

  • 醫院和診所
    • 概述
    • 醫院和診所市場、收入和 2030 年預測
  • 門診手術中心
    • 概述
    • 門診手術中心市場、收入與 2030 年預測
  • 居家護理
    • 概述
    • 家庭護理市場、收入和 2030 年預測
  • 其他
    • 概述
    • 其他市場、收入和 2030 年預測

第 10 章：歐洲微生物組治療市場 - 國家分析

    • 英國
      • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區

第 11 章：產業格局

  • 概述
  • 歐洲微生物組治療市場的成長策略

第 12 章：公司簡介

  • YSOPIA Bioscience SA
  • Ferring Holdings SA
  • Enterome SA
  • Caelus Health BV
  • Vedanta Biosciences Inc

第 13 章：附錄

Product Code: BMIRE00029955

The Europe microbiome therapeutics market was valued at US$ 97.74 million in 2022 and is expected to reach US$ 212.52 million by 2030; it is estimated to record a CAGR of 10.2% from 2022 to 2030.

Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives Europe Microbiome Therapeutics Market

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. For instance, in March 2023, mbiomics GmbH, a German microbiome biotech company, developed the first generation of effective microbiome-based therapeutics. It received a funding of 13 million (US$ 15 million) from MIG Capital. The funding will allow to build the platform, which will accelerate the identification of first-lead drug candidates and speed up research efforts toward clinical validation. As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

Europe Microbiome Therapeutics Market Overview

Microbiome therapeutic research companies in Germany are focused on calling other companies to invest in their research activities to improve the quality of research being conducted for microbiome product development. In March 2023, mbiomics GmbH, a German biotech company focused on the microbiome, received ~US$ 15 million (13 million) in a series A financing round led by MIG Capital. mbiomics used the proceeds to embark on strategic partnerships, significantly expanding their Munich laboratory facilities and R&D teams in Germany. In some FMT procedures, infectious agents may be transferred from donor to patient, which affects the outcomes. Hence, Germany has set particular regulations for the use of microbiome or FMT procedures. In Germany, FMT drugs are regulated as a medicinal product; however, the use of this product can be done only when no other treatment is working on conditions such as C. difficile infections and gut infections. Hence, despite an upsurge in investments in research on microbiome therapeutics, regulations regarding the use of these therapeutic products may hamper the growth of the Europe microbiome therapeutics market in Germany.

Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Europe Microbiome Therapeutics Market Segmentation

The Europe microbiome therapeutics market is segmented based on type, application, end user, and country.

Based on type, the Europe microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the Europe microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The metabolic disorder and obesity segment held the largest share in 2022.

By end user, the Europe microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.

Based on country, the Europe microbiome therapeutics market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe microbiome therapeutics market in 2022.

Caelus Health BV, Enterome SA, Ferring Holdings SA, Vedanta Biosciences Inc, and YSOPIA Bioscience SA are some of the leading companies operating in the Europe microbiome therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Microbiome Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 Europe PEST Analysis

5. Europe Microbiome Therapeutics Market - Key Industry Dynamics

  • 5.1 Europe Microbiome Therapeutics Market - Key Industry Dynamics
  • 5.2 Key Market Drivers
    • 5.2.1 Potential of Gut Microbiota in Maintaining Human Health
    • 5.2.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
  • 5.3 Key Market Restraints
    • 5.3.1 High Cost of Development and Production
  • 5.4 Key Market Opportunities
    • 5.4.1 Increasing R&D to Gain Better Understanding of Human Microbiome
  • 5.5 Key Future Trends
    • 5.5.1 Technological Advancement in Human Microbiome Therapeutics
  • 5.6 Impact of Drivers and Restraints:

6. Microbiome Therapeutics Market - Europe Market Analysis

7. Europe Microbiome Therapeutics Market Analysis - Type

  • 7.1 Therapeutics
    • 7.1.1 Overview
    • 7.1.2 Therapeutics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 7.2 Procedure
    • 7.2.1 Overview
    • 7.2.2 Procedure Market, Revenue and Forecast to 2030 (US$ Thousand)

8. Europe Microbiome Therapeutics Market Analysis - Application

  • 8.1 Metabolic Disorder and Obesity
    • 8.1.1 Overview
    • 8.1.2 Metabolic Disorder and Obesity Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.2 C. Difficile Infection (CDI)
    • 8.2.1 Overview
    • 8.2.2 C. Difficile Infection (CDI) Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.3 Inflammatory Bowel Disease
    • 8.3.1 Overview
    • 8.3.2 Inflammatory Bowel Disease Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

9. Europe Microbiome Therapeutics Market Analysis - End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Overview
    • 9.1.2 Hospitals and Clinics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.2 Ambulatory Surgical Centers
    • 9.2.1 Overview
    • 9.2.2 Ambulatory Surgical Centers Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.3 Homecare
    • 9.3.1 Overview
    • 9.3.2 Homecare Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

10. Europe Microbiome Therapeutics Market - Country Analysis

  • 10.1. Europe Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.1 Europe Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.2 UK
      • 10.1.2.1 UK: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.2.2 United Kingdom Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.2.2.1 UK: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.2.3 UK: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.2.4 UK: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.3 Germany
      • 10.1.3.1 Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.3.2 Germany: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.3.2.1 Germany: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.3.3 Germany: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.3.4 Germany: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.4 France
      • 10.1.4.1 France: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.4.2 France: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.4.2.1 France: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.4.3 France: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.4.4 France: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.5 Italy
      • 10.1.5.1 Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.5.2 Italy: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.5.2.1 Italy: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.5.3 Italy: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.5.4 Italy: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.6 Spain
      • 10.1.6.1 Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.6.2 Spain: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.6.2.1 Spain: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.6.3 Spain: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.6.4 Spain: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.7 Rest of Europe
      • 10.1.7.1 Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.7.2 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.7.2.1 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.7.3 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.7.4 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by End User

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Europe Microbiome Therapeutics Market

12. Company Profiles

  • 12.1 YSOPIA Bioscience SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Ferring Holdings SA
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Enterome SA
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Caelus Health BV
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Vedanta Biosciences Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Microbiome Therapeutics Market Segmentation
  • Table 2. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - Type
  • Table 3. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - Therapeutics
  • Table 4. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - Application
  • Table 5. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - End User
  • Table 6. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Country
  • Table 7. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 8. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 9. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 10. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 11. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 12. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 13. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 14. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 15. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 16. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 17. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 18. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 19. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 20. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 21. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 22. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 23. ADULT OBESITY, 2030
  • Table 24. CHILD OBESITY, 2030
  • Table 25. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 26. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 27. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 28. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 29. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 30. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 31. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 32. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 33. Recent Growth Strategies in Europe Microbiome Therapeutics Market
  • Table 34. Glossary of Terms, Europe Microbiome Therapeutics Market

List Of Figures

  • Figure 1. Europe Microbiome Therapeutics Market Segmentation, By Country
  • Figure 2. Europe PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Microbiome Therapeutics Market Revenue (US$ Thousand), 2022 - 2030
  • Figure 5. Europe Microbiome Therapeutics Market Share (%) - Type, 2022 and 2030
  • Figure 6. Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 7. Procedure Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 8. Europe Microbiome Therapeutics Market Share (%) - Application, 2022 and 2030
  • Figure 9. Metabolic Disorder and Obesity Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 10. C. Difficile Infection (CDI) Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 11. Inflammatory Bowel Disease Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 12. Others Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 13. Europe Microbiome Therapeutics Market Share (%) - End User, 2022 and 2030
  • Figure 14. Hospitals and Clinics Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 15. Ambulatory Surgical Centers Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 16. Homecare Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 17. Others Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 18. Europe Microbiome Therapeutics Market Breakdown by Key Countries - Revenue (2022) (US$ Thousand)
  • Figure 19. Europe Microbiome Therapeutics Market Breakdown by Key Countries, 2022 and 2030 (%)
  • Figure 20. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 21. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 22. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 23. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 24. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 25. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)